The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

In a report released today, Charles Rhyee from TD Cowen maintained a Buy rating on CVS Health (CVS – Research Report), with a price target of

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. During the quarter,

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide range of health solutions in the United States. With offerings that span pharmacy benefit management,

In 2018, CVS acquired the insurer, Aetna, and in 2007, the company acquired pharmacy services provider Caremark Rx. Adding Signify Health to the mix presents an opportunity for CVS to drive ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

CVS Caremark, Express Scripts ... based on a subset of medications that represent less than 2% of what our health plans spend on medications in a year.” Express Scripts sued the FTC in September ...

CVS Health Corporation is a vertically integrated healthcare corporation in the United States. The company owns a leading healthcare benefits provider, a leading pharmacy benefits